vTv Therapeutics Reports Board and Officer Changes
Ticker: VTVT · Form: 8-K · Filed: Feb 27, 2025 · CIK: 1641489
| Field | Detail |
|---|---|
| Company | Vtv Therapeutics Inc. (VTVT) |
| Form Type | 8-K |
| Filed Date | Feb 27, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: management-change, board-of-directors, executive-compensation
Related Tickers: VTVT
TL;DR
vTv Therapeutics shakes up its board and exec comp. New faces, new pay plans.
AI Summary
vTv Therapeutics Inc. announced on February 24, 2025, a change in its board of directors. Specifically, the company reported the departure of certain officers and the election of new directors, alongside updates to compensatory arrangements for its key executives. The filing details these changes in corporate governance and executive compensation.
Why It Matters
Changes in a company's board of directors and executive compensation can signal shifts in strategy, operational focus, or financial health, impacting investor confidence and future performance.
Risk Assessment
Risk Level: medium — Changes in board composition and executive compensation can indicate underlying issues or strategic shifts that may carry financial risks.
Key Numbers
- 001-37524 — SEC File Number (Identifies the company's filing with the SEC.)
- 47-3916571 — IRS Employer Identification No. (Company's tax identification number.)
Key Players & Entities
- vTv Therapeutics Inc. (company) — Registrant
- February 24, 2025 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of incorporation
- High Point, NC (location) — Principal executive offices address
FAQ
What specific roles have been affected by the departure of officers?
The filing indicates the departure of 'certain officers' but does not specify the exact roles in the provided text.
Who are the newly elected directors?
The filing mentions the election of directors but does not list their names in the provided text.
What are the details of the compensatory arrangements for certain officers?
The filing notes changes to compensatory arrangements but does not provide specific details on the new terms or amounts in the provided text.
When was the earliest event reported in this 8-K filing?
The earliest event reported was on February 24, 2025.
What is the principal executive office address of vTv Therapeutics Inc.?
The principal executive office is located at 3980 Premier Drive, Suite 310, High Point, NC 27265.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on February 27, 2025 regarding vTv Therapeutics Inc. (VTVT).